MEA Acute LymphocyticLymphoblastic Leukemia (ALL) Diagnostics Market

Description

List of Tables

The Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market is projected to register a substantial CAGR of 5.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030

Market Segmentation:

Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (B-cell Lymphoblastic Leukemia/Lymphoma, and T-cell Lymphoblastic Leukemia), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:

Increase in awareness about the leukemia cancer diagnostics

Rising preference for preventive health check-ups

Market Players:

Some of the major players operating in the Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific, Inc.

QIAGEN

Abbott

Merck KGgA

Hologic, Inc.

Agilent Technologies, Inc.

DiaSorin S.p.A.

Illumina, Inc.

Quest Diagnostics Incorporated

Siemens Medical Solutions USA, Inc.

Bio-Rad Laboratories, Inc.

Koninklijke Philips N.V.

MinFound Medical Systems Co., Ltd

1 INTRODUCTION 23

1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 23
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 26

2 MARKET SEGMENTATION 29

2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 CURRENCY AND PRICING 31
2.5 DBMR TRIPOD DATA VALIDATION MODEL 32
2.6 MULTIVARIATE MODELLING 35
2.7 PRODUCT TYPE LIFELINE CURVE 35
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.9 DBMR MARKET POSITION GRID 37
2.10 MARKET TESTING TYPE COVERAGE GRID 39
2.11 VENDOR SHARE ANALYSIS 40
2.12 SECONDARY SOURCES 41
2.13 ASSUMPTIONS 41

3 EXECUTIVE SUMMARY 42

4 PREMIUM INSIGHTS 45

4.1 PESTEL ANALYSIS 46
4.2 PORTER'S FIVE FORCES 47
4.3 INDUSTRY INSIGHTS 48

5 EPIDEMIOLOGY 50

6 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, REGULATIONS 51

7 MARKET OVERVIEW 54

7.1 DRIVERS 56
- 7.1.1 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 56
- 7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 56
- 7.1.3 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 57
- 7.1.4 GROWING PREVALENCE OF LEUKEMIA CANCER 57
7.2 RESTRAINTS 59
- 7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 59
- 7.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 60
7.3 OPPORTUNITIES 60
- 7.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 60
- 7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 61
- 7.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 61
7.4 CHALLENGES 62
- 7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 62
- 7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 63

8 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE 64

8.1 OVERVIEW 65
8.2 INSTRUMENTS 68
- 8.2.1 BIOPSY INSTRUMENTS 69
  - 8.2.1.1 BONE MARROW BIOPSY 69
  - 8.2.1.2 NEEDLE BIOPSY 69
  - 8.2.1.3 SURGEON BIOPSY 70
  - 8.2.1.4 OTHERS 70
- 8.2.2 PATHOLOGY-BASED INSTRUMENTS 70
  - 8.2.2.1 PCR INSTRUMENTS 70
  - 8.2.2.2 SLIDE STAINING SYSTEMS 70
  - 8.2.2.3 TISSUE PROCESSING SYSTEMS 70
  - 8.2.2.4 CELL PROCESSORS 71
  - 8.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 71
- 8.2.3 IMAGING INSTRUMENTS 71
  - 8.2.3.1 ULTRASOUND SYSTEMS 71
  - 8.2.3.2 CT SYSTEMS 71
  - 8.2.3.3 MRI SYSTEMS 71
  - 8.2.3.4 OTHERS 72
- 8.2.4 OTHERS 72
8.3 CONSUMABLES & ACCESSORIES 72
- 8.3.1 KITS 73
  - 8.3.1.1 PCR KITS 73
  - 8.3.1.2 DNA POLYMERASE KITS 73
  - 8.3.1.3 NUCLEIC ACID ISOLATION KITS 73
  - 8.3.1.4 OTHERS 74
- 8.3.2 REAGENTS 74
  - 8.3.2.1 ASSAYS 74
  - 8.3.2.2 BUFFERS 74
  - 8.3.2.3 PRIMERS 74
  - 8.3.2.4 OTHERS 74
- 8.3.3 PROBES 75
- 8.3.4 OTHER CONSUMABLES 75

9 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE 76

9.1 OVERVIEW 77
9.2 BIOPSY 80
- 9.2.1 BONE MARROW BIOPSY 81
- 9.2.2 NEEDLE BIOPSY 81
- 9.2.3 SURGEON BIOPSY 81
- 9.2.4 OTHERS 81
9.3 BLOOD TEST 82
- 9.3.1 BLOOD CHEMISTRY TESTS 83
- 9.3.2 COMPLETE BLOOD COUNT (CBC) 83
- 9.3.3 OTHERS 83
9.4 IMAGING TEST 83
- 9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 84
- 9.4.2 MRI 84
- 9.4.3 POSITRON EMISSION TOMOHRAPHY (PET) SCAN 85
- 9.4.4 OTHERS 85
9.5 OTHERS 85

10 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE 86

10.1 OVERVIEW 87
10.2 B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA 90
- 10.2.1 EARLY PRE-B ALL 91
- 10.2.2 COMMON ALL 91
- 10.2.3 PRE-B ALL 91
- 10.2.4 MATURE B-CELL ALL 91
10.3 T-CELL LYMPHOBLASTIC LEUKEMIA 91
- 10.3.1 PRE-T ALL 92
- 10.3.2 MATURE T-CELL ALL 92

11 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP 93

11.1 OVERVIEW 94
11.2 BELOW 21 97
11.3 21-29 98
11.4 30-65 99
11.5 65 AND ABOVE 100

12 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER 101

12.1 OVERVIEW 102
12.2 MALE 105
12.3 FEMALE 106

13 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER 107

13.1 OVERVIEW 108
13.2 HOSPITALS 111
13.3 ASSOCIATED LABS 111
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 112
13.5 DIAGNOSTIC IMAGING CENTERS 113
13.6 CANCER RESEARCH INSTITUTES 113
13.7 OTHERS 114

14 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 115

14.1 OVERVIEW 116
14.2 DIRECT TENDER 119
14.3 RETAIL SALES 120

15 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION 121

15.1 MIDDLE EAST AND AFRICA 122
- 15.1.1 SOUTH AFRICA 133
- 15.1.2 EGYPT 138
- 15.1.3 SAUDI ARABIA 143
- 15.1.4 ISRAEL 148
- 15.1.5 UAE 153
- 15.1.6 REST OF MIDDLE EAST AND AFRICA 158

16 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, COMPANY LANDSCAPE 159

16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 159

17 SWOT ANALYSIS 160

18 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 161

18.1 F. HOFFMANN-LA ROCHE LTD. 161
- 18.1.1 COMPANY SNAPSHOT 161
- 18.1.2 REVENUE ANALYSIS 161
- 18.1.3 COMPANY SHARE ANALYSIS 162
- 18.1.4 PRODUCT PORTFOLIO 162
- 18.1.5 RECENT DEVELOPMENT 162
18.2 THERMO FISHER SCIENTIFIC INC. 163
- 18.2.1 COMPANY SNAPSHOT 163
- 18.2.2 REVENUE ANALYSIS 163
- 18.2.3 COMPANY SHARE ANALYSIS 164
- 18.2.4 PRODUCT PORTFOLIO 164
- 18.2.5 RECENT DEVELOPMENT 164
18.3 QIAGEN 165
- 18.3.1 COMPANY SNAPSHOT 165
- 18.3.2 REVENUE ANALYSIS 165
- 18.3.3 COMPANY SHARE ANALYSIS 166
- 18.3.4 PRODUCT PORTFOLIO 166
- 18.3.5 RECENT DEVELOPMENT 166
18.4 ABBOTT 167
- 18.4.1 COMPANY SNAPSHOT 167
- 18.4.2 REVENUE ANALYSIS 167
- 18.4.3 COMPANY SHARE ANALYSIS 168
- 18.4.4 PRODUCT PORTFOLIO 168
- 18.4.5 RECENT DEVELOPMENT 168
18.5 SIEMENS MEDICAL SOLUTIONS USA, INC. 169
- 18.5.1 COMPANY SNAPSHOT 169
- 18.5.2 REVENUE ANALYSIS 169
- 18.5.3 COMPANY SHARE ANALYSIS 170
- 18.5.4 PRODUCT PORTFOLIO 170
- 18.5.5 RECENT DEVELOPMENT 170
18.6 MERCK KGAA 171
- 18.6.1 COMPANY SNAPSHOT 171
- 18.6.2 REVENUE ANALYSIS 171
- 18.6.3 PRODUCT PORTFOLIO 172
- 18.6.4 RECENT DEVELOPMENT 172
18.7 HOLOGIC INC. 173
- 18.7.1 COMPANY SNAPSHOT 173
- 18.7.2 REVENUE ANALYSIS 173
- 18.7.3 PRODUCT PORTFOLIO 174
- 18.7.4 RECENT DEVELOPMENT 174
18.8 AGILENT TECHNOLOGIES, INC. 175
- 18.8.1 COMPANY SNAPSHOT 175
- 18.8.2 REVENUE ANALYSIS 175
- 18.8.3 PRODUCT PORTFOLIO 176
- 18.8.4 RECENT DEVELOPMENT 176
18.9 BD 177
- 18.9.1 COMPANY SNAPSHOT 177
- 18.9.2 REVENUE ANALYSIS 177
- 18.9.3 PRODUCT PORTFOLIO 178
- 18.9.4 RECENT DEVELOPMENT 178
18.10 BIOMERIEUX SA 179
- 18.10.1 COMPANY SNAPSHOT 179
- 18.10.2 REVENUE ANALYSIS 179
- 18.10.3 PRODUCT PORTFOLIO 180
- 18.10.4 RECENT DEVELOPMENTS 180
18.11 BIO-RAD LABORATORIES, INC. 181
- 18.11.1 COMPANY SNAPSHOT 181
- 18.11.2 REVENUE ANALYSIS 181
- 18.11.3 PRODUCT PORTFOLIO 182
- 18.11.4 RECENT DEVELOPMENT 182
18.12 DIASORIN S.P.A. 183
- 18.12.1 COMPANY SNAPSHOT 183
- 18.12.2 REVENUE ANALYSIS 183
- 18.12.3 PRODUCT PORTFOLIO 184
- 18.12.4 RECENT DEVELOPMENTS 184
18.13 EXACT SCIENCE CORPORATION 185
- 18.13.1 COMPANY SNAPSHOT 185
- 18.13.2 REVENUE ANALYSIS 185
- 18.13.3 PRODUCT PORTFOLIO 186
- 18.13.4 RECENT DEVELOPMENT 186
18.14 ILLUMINA, INC. 187
- 18.14.1 COMPANY SNAPSHOT 187
- 18.14.2 REVENUE ANALYSIS 187
- 18.14.3 PRODUCT PORTFOLIO 188
- 18.14.4 RECENT DEVELOPMENT 188
18.15 KONINKLIJKE PHILIPS N.V. 189
- 18.15.1 COMPANY SNAPSHOT 189
- 18.15.2 REVENUE ANALYSIS 189
- 18.15.3 PRODUCT PORTFOLIO 190
- 18.15.4 RECENT DEVELOPMENT 190
18.16 MEDONICA CO. LTD 191
- 18.16.1 COMPANY SNAPSHOT 191
- 18.16.2 PRODUCT PORTFOLIO 191
- 18.16.3 RECENT DEVELOPMENT 191
18.17 MICHAEL DIAGNOSTICS LTD 192
- 18.17.1 COMPANY SNAPSHOT 192
- 18.17.2 PRODUCT PORTFOLIO 192
- 18.17.3 RECENT DEVELOPMENT 192
18.18 MINFOUND MEDICAL SYSTEMS CO., LTD 193
- 18.18.1 COMPANY SNAPSHOT 193
- 18.18.2 PRODUCT PORTFOLIO 193
- 18.18.3 RECENT DEVELOPMENT 193
18.19 MYRIAD GENETICS, INC. 194
- 18.19.1 COMPANY SNAPSHOT 194
- 18.19.2 REVENUE ANALYSIS 194
- 18.19.3 PRODUCT PORTFOLIO 195
- 18.19.4 RECENT DEVELOPMENT 195
18.20 PLEXBIO 196
- 18.20.1 COMPANY SNAPSHOT 196
- 18.20.2 PRODUCT PORTFOLIO 196
- 18.20.3 RECENT DEVELOPMENTS 196
18.21 QUEST DIAGNOSTICS INCORPORATED 197
- 18.21.1 COMPANY SNAPSHOT 197
- 18.21.2 REVENUE ANALYSIS 197
- 18.21.3 PRODUCT PORTFOLIO 198
- 18.21.4 RECENT DEVELOPMENTS 198
18.22 STERNMED GMBH 199
- 18.22.1 COMPANY SNAPSHOT 199
- 18.22.2 PRODUCT PORTFOLIO 199
- 18.22.3 RECENT DEVELOPMENTS 199
18.23 TIME MEDICAL HOLDING 200
- 18.23.1 COMPANY SNAPSHOT 200
- 18.23.2 PRODUCT PORTFOLIO 200
- 18.23.3 RECENT DEVELOPMENT 200

19 QUESTIONNAIRE 201

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SEGMENTATION 29
FIGURE 2 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DATA TRIANGULATION 32
FIGURE 3 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DROC ANALYSIS 33
FIGURE 4 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 34
FIGURE 5 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 34
FIGURE 6 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 36
FIGURE 7 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 37
FIGURE 8 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID 39
FIGURE 9 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 40
FIGURE 10 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SEGMENTATION 44
FIGURE 11 INCREASE IN THE AWARENESS ABOUT LEUKEMIA IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET IN THE FORECAST PERIOD 45
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET IN 2023 & 2030 45
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/ LYMPHOBLASTIC (ALL) LEUKEMIA DIAGNOSTICS MARKET 55
FIGURE 14 MIDDLE EAST & AFRICA LEUKEMIA INCIDENCE (BOTH SEXES) 58
FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE (BOTH SEXES) 59
FIGURE 16 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 65
FIGURE 17 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 66
FIGURE 18 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 66
FIGURE 19 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY PRODUCT TYPE, LIFELINE CURVE 67
FIGURE 20 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, 2022 77
FIGURE 21 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 78
FIGURE 22 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 78
FIGURE 23 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 79
FIGURE 24 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 87
FIGURE 25 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 88
FIGURE 26 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 88
FIGURE 27 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 89
FIGURE 28 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, 2022 94
FIGURE 29 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 95
FIGURE 30 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 95
FIGURE 31 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 96
FIGURE 32 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, 2022 102
FIGURE 33 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION) 103
FIGURE 34 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030) 103
FIGURE 35 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY GENDER, LIFELINE CURVE 104
FIGURE 36 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, 2022 108
FIGURE 37 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 109
FIGURE 38 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 109
FIGURE 39 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 110
FIGURE 40 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 116
FIGURE 41 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 117
FIGURE 42 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 117
FIGURE 43 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 118
FIGURE 44 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SNAPSHOT (2022) 123
FIGURE 45 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022) 125
FIGURE 46 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 125
FIGURE 47 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 126
FIGURE 48 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 126
FIGURE 49 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 159